{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:49:12Z","timestamp":1747147752479,"version":"3.40.5"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>Dabigatran is the first of four direct\u2010acting oral anticoagulants approved to prevent stroke in adult patients with atrial fibrillation using a fixed two\u2010dose scheme compared with warfarin dosing adjusted to a prothrombin time range associated with optimal risk reduction in stroke and serious bleeding. The pivotal phase III trial found dabigatran, depending on dose, is superior to warfarin in stroke reduction and similar in bleeding risk while also showing dabigatran efficacy and safety correlate with steady\u2010state plasma concentrations. Because the relationship between dabigatran dose and plasma concentration is highly variable, a previously developed population pharmacokinetic model of over 9,000 clinical trial patients was used as a basis for simulations comparing the performance of dosing via the drug label to other proposed doses and regimens. Assessment of dosing regimen performance was based on simulations of trough plasma levels within the therapeutic concentration range of 75\u2013150\u2009ng\/mL over a renal function range of 15\u2013250\u2009mL\/min creatinine clearance, representing extremes for real\u2010world patients. An improved regimen that best achieves this therapeutic range was identified, requiring five different dosing schedules, corresponding to specified renal function ranges, compared with the two approved in the label. The discussion focuses on how this information could better inform patient outcomes and future dabigatran development.<\/jats:p>","DOI":"10.1002\/cpt.2902","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T08:27:56Z","timestamp":1680856076000},"page":"362-370","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress\u2010Testing Renal Function Range in Real World Patients"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-6239","authenticated-orcid":false,"given":"J. Robert","family":"Powell","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Al Qaraghuli","sequence":"additional","affiliation":[{"name":"Cognigen Division Simulations Plus, Inc.  Buffalo New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Fiedler\u2010Kelly","sequence":"additional","affiliation":[{"name":"Cognigen Division Simulations Plus, Inc.  Buffalo New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-5686","authenticated-orcid":false,"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0602-9026","authenticated-orcid":false,"given":"Daniel","family":"Weiner","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.104"},{"key":"e_1_2_10_3_1","unstructured":"Br. Med. J. 2014 Impact of dabigatran dose adjustment on clinical outcome in AF patients: a clinical trial simulation analysis"},{"key":"e_1_2_10_4_1","unstructured":"Edoxaban label<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf>. Accessed April 20 2023."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1603156"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430050045005"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.59.2.250"},{"key":"e_1_2_10_8_1","first-page":"1309","article-title":"Atrial fibrillation in athletes: pathophysiology, clinical presentation, evaluation and management","volume":"8","author":"Turagam M.K.","year":"2015","journal-title":"J Atr Fibrillation"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12479"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0007"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1923"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12766"},{"key":"e_1_2_10_13_1","unstructured":"Unger E.F.Center for Drug Evaluation and Research Application Number 22\u2010512: Deputy Office Director Decisional Memo<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022512Orig1s000SumR.pdf>."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.10.002"},{"key":"e_1_2_10_15_1","unstructured":"TempleR.NOAC dosing: precision dosing\u2010Yes!<https:\/\/4cuvx726wz7k26wyc3p0v11q\u2010wpengine.netdna\u2010ssl.com\/wp\u2010content\/uploads\/2020\/09\/S2_1a_Temple.pdf>"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04498.x"},{"key":"e_1_2_10_17_1","unstructured":"Baron K.(2017).Mrgsolve: simulate from ODE\u2010based population PK\/PD and systems pharmacology models. R package version 0.8.10 <https:\/\/CRAN.R\u2010project.org\/package=mrgsolve>"},{"volume-title":"Rstudio: Integrated Development for R","year":"2020","author":"Rstudio Team","key":"e_1_2_10_18_1"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_10_20_1","unstructured":"Application number 22\u2010512 Dabigatran etexilate mesylate for stroke prevention Clinical Pharmacology NDA Review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022512Orig1s000ClinPharmR_Corrrected%203.11.2011.pdf>"},{"key":"e_1_2_10_21_1","unstructured":"Dabigatran label<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022512s007lbl.pdf>"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-017-0982-4"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1976.03270130027021"},{"key":"e_1_2_10_24_1","unstructured":"Dabigatran Prevention of stroke and systemic embolism in atrial fibrillation NDA Clinical Review. (2010) <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022512Orig1s000MedR.pdf>83."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61194-4"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056355"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2131"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.10.015"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.24.1.123"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:37:57Z","timestamp":1699364277000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/cpt.2902"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2902","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"type":"print","value":"0009-9236"},{"type":"electronic","value":"1532-6535"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"2023-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}